Dossier assessment
Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with advanced epithelial (FIGO stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
Added benefit not proven.
Project details
- Project no.
- A20-98
- Commission
- Commission awarded on 26.11.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Niraparib (ovarian cancer) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed